Non-Small Cell Lung Cancer-Derived Soluble Mediators and Prostaglandin E2 Enhance Peripheral Blood Lymphocyte IL-10 Transcription and Protein Production

Journal of Immunology

Volumn 157, Issue 12, 1996, Pages 5512-5520

  Huang, Min ^a   Sharma, Sherven ^a   Mao, Jenny T ^a   Dubinett, Steven M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME INHIBITOR; GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 10; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; INDOMETHACIN; INTERFERON TYPE II; INTERLEUKIN-10; LUNG NEOPLASMS; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030589376     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444.
2. Mitra, R. S., T. A. Judge, F. O. Nestle, L. A. Turka, and B. J. Nickoloff. 1995. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. J. Immunol. 154:2668.
3. de Waal-Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. Te Velde, C. Fidgor, K. Johnson, R. Kastelein, H. Yssel, and J. E. De Vries, 1991. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class-II major histocompatibility complex expression. J. Exp. Med. 174:915.
4. Taga, K., and G. Tosato. 1992. IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol. 148:1143.
5. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815.
6. Mosmann, T., and Moore, K. W. 1991. The role of IL-10 in cross-regulation of TH1 and TH2 responses. Immunol. Today 12:A49.
7. Huang, M., J. Wang, P. Lee, S. Sharma, J. T. Mao, H. Meissner, K. Uyemura, R. Modlin, J. Wollman, and S. M. Dubinett. 1995. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55:3847.
8. Yamamura, M., R. L. Modlin, J. D. Ohmen, and R. L. Moy. 1993. Local expression of anti-inflammatory cytokines in cancer. J. Clin. Invest. 91:1005.
9. Smith, D. R., S. L. Kunkel, M. D. Burdick, C. A. Wilke, M. B. Orringer, R. I. Whyte, and R. M. Strieter. 1994. Production of interleukin-10 by human bronchogenic carcinoma. Am. J. Pathol. 145:18.
10. Maeda, H., and A. Shiraishi. 1996. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10 mediated pathways in tumor-bearing mice. J. Immunol. 156:73.
11. Lee, P., M. Huang, J. Wang, S. Sharma, T. Beroiza, S. Ahmed, and S. M. Dubinett. 1994. Transforming growth factor-beta specific antisense phosphorothioate oligonucleotides abrogate lung tumor-associated immunosuppression. J. Immunol. 152:3222.
12. Dubinett, S. M., M. Huang, S. Dhanani, J. Wang, and T. Beroiza. 1993. Down-regulation of macrophage transforming growth factor-β messenger RNA expression by interleukin-7. J. Immunol. 151:6670.
13. 2 J. Immunol. 153:1674.
14. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol. 155:2240.
15. 2 formation and histamine action in cancer immunotherapy. Cancer Immunol. Immunother. 37:251.
16. 2 content in bronchoalveolar lavage fluid and intrathoracic malignancy. Chest 106:166.
17. McLemore, T. L., W. C. Hubhard, C. L. Litterst, M. C. Liu, S. Miller, and N. A. McMahon. 1988. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 48:3140.
18. 2 inhibits production of Th1 lymphokines but not Th2 lymphokines. J. Immunol. 146:108.
19. Gajewski, T. F., S. R. Schell, and F. W. Fitch. 1990. Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones. J. Immunol. 144:4110.
20. Phipps, R. P., S. H. Stein, and R. L. Roper. 1991. A new view of prostaglandin E regulation of the immune response. Immunol. Today 12:349.
21. 2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:775.
22. 2 and the immune response. Mol. Med. Today 1:61.
23. Panettieri, R., A. Lazaar, E. Pure, and S. Albelda. 1995. Activation of cAMP-dependent pathways in human airway smooth muscle cells inhibits TNF-α-induced ICAM-1 and VCAM-1 expression and T lymphocyte adhesion. J. Immunol. 154:2358.
24. 2. J. Exp. Med. 180: 2365.
25. Chijiwa, T., A. Mishima, M. Hagiwara, M. Sano, K. Hayashi, T. Inoue, K. Naito, T. Toshioka, and H. Hidaka. 1990. Inhibition of forskolin-induced neurite out-growth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265:5267.
26. Dostmann, W., S. Taylor, H. Genieser, B. Jastorff, S. Doskeland, and D. Ogreid. 1990. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J. Biol. Chem. 265:10484.
27. Dostmann, W. 1995. (RP)-cAMPS inhibits the cAMP-dependent protein kinase by blocking the cAMP-inducing conformational transition. FEBS Lett. 375:231.
28. Dubinett, S. M., M. Huang, S. Dhanani, J. Economou, G. Dougherty, J. Wang, and W. McBride. 1995. Down-regulation of murine fibrosarcoma transforming growth factor-β1 expression by interleukin 7. J. Natl. Cancer Inst. 87:593.
29. Dubinett, S. M., and R. L. Kradin. 1993. Cytokine immunotherapy of non-small cell lung cancer. Reg. Immunol. 5:232.
30. Sulitzeanu, D. 1993. Immunosuppressive factors in human cancer. Adv. Cancer Res. 60:247.
31. Yoshino, I., T. Yano, M. Murata, T. Ishida, K. Sugimachi, G. Kimura, and K. Nomoto. 1992. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res. 52:775.
32. 2 and the growth of non-small cell lung cancer. Proc. Am Assoc. Cancer Res. 36:601.
33. Mao, J., M. Huang, J. Wang, S. Sharma, and S. Dubinett. 1996. Cox-2-specific antisense oligodeoxynucleotides inhibit lung cancer cell-induced IL-10 production in human peripheral blood lymphocytes. Am. J. Resp. Crit. Care Med. 153: A109.
34. Young, M. R. I., M. A. Wright, J. P. Matthews, I. Malik, and M. Prechel. 1996. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J. Immunol. 156:1916.
35. Kambayashi, T., H. R. Alexander, M. Fong, and G. Strassmann. 1995. Potential involvement of IL-10 in suppressing tumor-associated macrophages. J. Immunol. 154:3383.
36. 2 inhibits B lymphocyte activation by a cAMP-dependent mechanism: PGE-inducible regulatory proteins. Cell. Immunol. 154:296.
37. 2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J. Immunol. 148:2845.
38. Krammer, G. 1988. The adenylate cyclase cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9:22.
39. Kambayashi, T., C. Jacob, D. Zhou, N. Mazurek, M. Fong, and G. Strassmann. 1995. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155:4909.
40. Ho, A., R. Wiest, T. Ogiwara, G. Murdoch, and C. Chik. 1995. Potentiation of agonist-stimulated cyclic AMP accumulation by tyrosine kinase inhibitors in rat pinealocytes. J. Neurochem. 65:1597.
41. Ueki, H., Y. Yamasaki, K. Higo, T. Motoyashiki, H. Kawabata, and T. Morita. 1995. Regulation of cyclic AMP phosphodiesterase activity by particulate protein tyrosine kinase and phosphotyrosine phosphatase activities. Biol. Pharm. Bull. 18:214.
42. Lala, P. K., M. Elkashab, R. S. Kerbel, and R. S. Parhar. 1990. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. Int. J. Immunol. 2:1149.
43. Mertens, W. C., V. H. C. Bramwell, F. Gwardy-Sridhar, W. Romano, D. Banerjee, and P. K. Lala. 1992. Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. Lancet 340:397.
44. Mertens, W. C., V. H. Bramwell, D. Banerjee, F. Gwadry-Sridhar, and P. K. Lala. 1993. Sustained indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced malignant melanoma: a phase II study. Clin. Oncol. 5:107.
45. Chiabrando, C., M. Broggini, M. N. Castagnoli, M. G. Donelli, A. Noseda, M. Visintainer, S. Garattini, and R. Fanelli. 1985. Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth. Cancer Res. 45:3605.
46. Maca, R. D. 1988. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice. J. Biol. Response Modif. 7:568.
47. Young, M. R., and S. Knies. 1984. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo. J. Natl. Cancer Inst. 72:919.
48. Young, M. R., and M. Newby. 1986. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice. J. Natl. Cancer Inst. 77:1255.
49. Young, M. R., E. Wheeler, and M. Newby. 1986. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J. Natl. Cancer Inst. 76:745.
50. Eisenthal, A. 1990. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular toxicity mediated by interleukin-2. Cancer Immunol. Immunother. 31:342.
51. Kharkevitch, D., D. Seito, G. Balch, T. Maeda, C. Balch, and K. Itoh. 1994. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int. J. Cancer 58:317.
52. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348.
53. Mosmann, T., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.
54. Reed, M. J. 1995. The discriminant-function test: a marker of Th1/Th2 cell cytokine secretion and breast tumour oestrogen synthesis. Mol. Med. Today 1:98.
55. Romagnani, S. 1991. Human Th1 and Th2 subsets: doubt no more. Immunol. Today 12:256.
56. Paul, W. E., and R. A. Seder. 1994. Lymphocyte responses and cytokines. Cell 76:241.
57. + cells that make TH2 cytokines and helper B cells. Science 260:1802.
58. + T cells secreting Th1 or Th2 cytokines. Immunity 2:271.
59. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279.
60. Rohrer, J. W., and J. H. Coggin, Jr. 1995. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol. 155:5719.
61. Pisa, P., E. Halapi, E. K. Pisa, E. Gerdin, C. Hising, A. Bucht, B. Gerdin, and R. Kiessling. 1992. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA 89:7708.
62. Maeurer, M., D. Martin, C. Castelli, E. Elder, G. Leder, W. Storkus, and M. Lotze. 1995. Host immune response in renal cell cancer: interleukin 4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol. Immunother. 41:111.
63. Novak, T. J., and E. V. Rothenberg. 1990. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc. Natl. Acad. Sci. USA 87:9353.
64. + T cells inhibits acquisition of ability to produce IFN-γ and IL-2, but not IL-4 and IL-5. J. Immunol. 155:4604.
65. + T cells. J. Immunol. 156:1722.
66. Schwartz, R. H. 1996. Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184:1.
67. + T cells. J. Exp. Med., 184:19.
68. Matsuda, M., F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q. Zhang, M. G. Masucci, and R. Kiessling. 1994. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and down-regulates HLA class I expression. J. Exp. Med. 180:2371.
69. Salazar-Onfray, F., M. Petersson, L. Franksson, M. Matsuda, T. Blankenstein, K. Kärre, and R. Kiessling. 1995. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol. 154:6291.
70. Wang, L., E. Goillot, and R. I. Tepper. 1994. IL-10 inhibits allorcactive cytotoxic T lymphocyte generation in vivo. Cell. Immunol. 159:152.